Skip to content

Evaluation of Efficacy of Shwasahara Dashemani vati in the management of Tamaka Shwasa

Evalaution of Efficacy of ShwasaHara Dashemani Vati and Shunthi Pushkarmooladi Vati in the management of Tamaka Shwas Bronchial Asthma in children -An open labeled Randomized Comparative Clinical Trial - EOEOSDVASPVITMOTSICAOLRCCT

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017259
Enrollment
60
Registered
2019-01-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J988- Other specified respiratory disorders

Interventions

Intervention1: Shwasahara Dashemani Vati ch su 4/37: shwasahara dashemani vati 10 contents named as Shathi Hedychium spicatumSm Pushkaramoola Inula racemosa Hook F Amlavetasa Rheum emodi Wal

Sponsors

Director IPGT and RA GAU JAMNAGAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients of 2 â?? 14 years of age group of either sex 2 Diagnosed cases of Tamaka Shwasa (Bronchial Asthma) with at least 2 episodes of asthma symptoms during the previous year 3 Patients on other drug therapy will be included only after completion of wash out period of 2 weeks 4 Mild persistent asthmatic patients 5 Patients on other drug therapy will be included only after completion

Exclusion criteria

Exclusion criteria: Children of age below 2 years and above 14 years 2 Patients with status asthmatics Evidence of active Concomitant Pulmonary Diseases other than asthma 3 Evidence of requirement of intubations for asthma or had been hospitalized for asthma within one month before Unresolved Sinus Disease or an unresolved upper or lower respiratory tract infection within 4 weeks 4 Concomitant severe de-compensated systemic disease (cardiovascular renal hepatic endocrine hematological neurological immunological).

Design outcomes

Primary

MeasureTime frame
relieve in the sign and symptom of shwasa roga or Bronchial asthmaTimepoint: 8 week

Secondary

MeasureTime frame
To prevent the recurrence of attack of breathlessness To increase the immunity against allergensTimepoint: 4 week

Countries

India

Contacts

Public ContactDr V K Kori

IPGT and RA

drkspatel2007@yahoo.co.in9427574566

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026